NanoViricides Inc. (NNVC)

[robi-1-kenobi]

I would say yes - EbolaCide could qualify for Orphan Drug Status in US and OUS. For US early development, granting of OD status, full development, approval and commercialization/use would result in a Priority Review Voucher.

So a ways to go, since they haven't even applied for Orphan Drug Status for EbolaCide.

There are varying estimates of worth (like anything, it depends on the buyers' motivations and competition).

Earlier this year, Biomarin sold a PRV to Regeneron for $67.5 million, I think.